Homologous recombination repair gene alterations occur across cutaneous adnexal carcinoma subtypes: a genomic cohort analysis, scoping review, and case report
Frontiers in Oncology · 18.11.2026 · 16
DOI: 10.3389/fonc.2026.2014671 ↗Kurz gefasst
Scoping Review in der Zeitschrift Frontiers in Oncology, online erschienen am 18.11.2026. Verfasst von Blake Sparkman und 3 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cutaneous adnexal carcinomas are rare malignancies without an approved systemic therapy for metastatic disease. Alterations in homologous recombination repair (HRR) genes confer sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors in other tumors, but their frequency in adnexal carcinomas is unknown. Existing evidence comes largely from case reports and small series limited to single tumor subtypes.
Methods
To estimate the prevalence of somatic and germline HRR alterations across adnexal carcinoma subtypes, we queried the Tempus Lens database. We supplemented this analysis with a scoping review of PubMed and Scopus for reports of ATM, CHEK2, PALB2, BRCA1, BRCA2, or RAD51 alterations in adnexal carcinomas. We also included a case of digital papillary adenocarcinoma, a subtype not previously represented in this literature, harboring a germline ATM variant.
Results
In the Tempus cohort (81 patients), 20 tumors (24.7%) carried at least one somatic HRR mutation, including 50.0% of sebaceous adenocarcinomas, and 5 of 36 patients with germline data (13.9%) carried an HRR variant. In the scoping review, 14 studies met inclusion criteria, of which 13 reported patient-level data on 41 patients. Including our case, 42 patients with 60 gene-level alterations were analyzed. BRCA1 was reported most often (38.1%), followed by BRCA2 (35.7%) and ATM (33.3%). Alterations spanned sebaceous, apocrine, eccrine, and follicular differentiation; sebaceous-lineage tumors accounted for 32 alterations (53.3%) and porocarcinoma for 18 (30.0%).
Conclusion
HRR alterations occur across multiple adnexal carcinoma subtypes, supporting consideration of somatic and germline testing in advanced disease. Whether these alterations predict benefit from PARP inhibition remains to be established.
Zitieren
APA
Sparkman, B., Poole, M., Rajeh, A., & Zhou, A. Y. (2026). Homologous recombination repair gene alterations occur across cutaneous adnexal carcinoma subtypes: a genomic cohort analysis, scoping review, and case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.2014671
Vancouver
Sparkman B, Poole M, Rajeh A, Zhou AY. Homologous recombination repair gene alterations occur across cutaneous adnexal carcinoma subtypes: a genomic cohort analysis, scoping review, and case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.2014671
BibTeX
@article{Sparkman2026,
author = {Sparkman, Blake and Poole, Mackenzie and Rajeh, Ahmad and Zhou, Alice Y.},
title = {Homologous recombination repair gene alterations occur across cutaneous adnexal carcinoma subtypes: a genomic cohort analysis, scoping review, and case report},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.2014671}
}
EUVIMED